Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gleave

Showing results (211-220 of 260) with videos related to

Pageof 26
Sort By:
Oncotarget|April 11, 2015
Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesiclesValentina R Minciacchi, Sungyong You, Cristiana Spinelli, et al.
JAMA Oncology|September 23, 2021
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerRahul Aggarwal, Nicholas R Rydzewski, Li Zhang, et al.
EMBO Reports|November 1, 2019
Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasisAmal M El-Naggar, Syam Prakash Somasekharan, Yemin Wang, et al.
EMBO Reports|May 29, 2025
Author Correction: Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasisAmal M El-Naggar, Syam Prakash Somasekharan, Yemin Wang, et al.
The Journal of Pathology|February 20, 2015
Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour developmentQian Wang, Rae-Anne Hardie, Andrew J Hoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate CancerJames A Eastham, Glenn Heller, Susan Halabi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 4, 2025
Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancerBetul Ersoy-Fazlioglu, Shreyas Lingadahalli, Umut Berkay Altintas, et al.
European Urology Oncology|September 25, 2025
Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional CohortsAshwini Uchil, Louis Lacombe, Hélène Hovington, et al.
Urologic Oncology|July 7, 2020
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancerDaniel H Kwon, Li Zhang, David A Quigley, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 14, 2016
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISHTamara L Lotan, Wei Wei, Olga Ludkovski, et al.
Pageof 26

Showing results (211-220 of 260) with videos related to

Sort By:
Pageof 26
Oncotarget|April 11, 2015
Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesiclesValentina R Minciacchi, Sungyong You, Cristiana Spinelli, et al.
JAMA Oncology|September 23, 2021
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerRahul Aggarwal, Nicholas R Rydzewski, Li Zhang, et al.
EMBO Reports|November 1, 2019
Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasisAmal M El-Naggar, Syam Prakash Somasekharan, Yemin Wang, et al.
EMBO Reports|May 29, 2025
Author Correction: Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasisAmal M El-Naggar, Syam Prakash Somasekharan, Yemin Wang, et al.
The Journal of Pathology|February 20, 2015
Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour developmentQian Wang, Rae-Anne Hardie, Andrew J Hoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate CancerJames A Eastham, Glenn Heller, Susan Halabi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 4, 2025
Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancerBetul Ersoy-Fazlioglu, Shreyas Lingadahalli, Umut Berkay Altintas, et al.
European Urology Oncology|September 25, 2025
Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional CohortsAshwini Uchil, Louis Lacombe, Hélène Hovington, et al.
Urologic Oncology|July 7, 2020
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancerDaniel H Kwon, Li Zhang, David A Quigley, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 14, 2016
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISHTamara L Lotan, Wei Wei, Olga Ludkovski, et al.
Pageof 26